Oct 2 (Reuters) - Theravance Inc :
* Theravance and alfa wassermann enter into agreement to develop and
commercialize velusetrag for gastroparesis
* Says companies will collaborate in the execution of a two-part phase 2
program
* Says financial terms of the transaction include funding of the phase 2
program by alfa wassermann
* Says is entitled to receive royalties on net sales by alfa wassermann ranging
from the low teens to 20%.
* Theravance-financial terms of deal include potential development, regulatory
and sales milestone payments of up to $53.5 million
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
((For more news, please click here ))